Contributions
Abstract: P1112
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 25 Biomarkers
Long non coding RNAs (LncRNAs) represent a novel class of transcripts, that are pervasively transcribed in the genome. Several lines of evidence correlate dysregulation of different LncRNAs to human diseases including neurological and psychiatric disorders, but their expression has not been exhaustively investigated in MS so far.
The main aim of this study was to identify a specific signature of cellular LncRNAs expression in Peripheral Blood Mononuclear Cells (PBMC) from a discovery cohort of MS patients compared with controls and to validate and replicate results in further independent validation populations.
LncRNA PCR arrays from SBI containing 90 common LncRNAs were used to screen LncRNA expression levels in PBMC from 5 patients with Relapsing Remitting (RR)-MS, 5 with Primary Progressive (PP)-MS and 5 age matched controls. Results were validated by Real time PCR in a further independent Italian cohort consisting of 30 PBMC samples from MS patients and 30 controls. Best hits were replicated, using droplet digital PCR, in a Belgian cohort made up by 24 MS patients and 23 controls.
In particular, in the Italian validation cohort ANRIL, TUG1, XIST (p< 0.0001) and SOX2OT (p< 0.001) were strongly down-regulated in RR-MS, while GOMAFU, HULC (p< 0.0001) and BACE-1AS (p< 0.001) showed a robust down-regulation both in RR and Progressive MS in comparison with controls.
NRON and TUG1 downregulation in MS patients compared with controls (p< 0.05 and p< 0.0001 respectively) was confirmed in the Belgian population.
Furthermore, considering the expression levels of LncRNAs known to be involved in brain function or neurological disorders, some important dysregulations emerged. The rationale of this study might then be used to set up a future study with the purpose of selecting potential biomarkers for disease aggressiveness and response to therapy.
LncRNAs profiling could thus represent a new challenge in the research of easy detectable biomarkers of disease susceptibility and progression.
Disclosure: nothing to disclose
Abstract: P1112
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 25 Biomarkers
Long non coding RNAs (LncRNAs) represent a novel class of transcripts, that are pervasively transcribed in the genome. Several lines of evidence correlate dysregulation of different LncRNAs to human diseases including neurological and psychiatric disorders, but their expression has not been exhaustively investigated in MS so far.
The main aim of this study was to identify a specific signature of cellular LncRNAs expression in Peripheral Blood Mononuclear Cells (PBMC) from a discovery cohort of MS patients compared with controls and to validate and replicate results in further independent validation populations.
LncRNA PCR arrays from SBI containing 90 common LncRNAs were used to screen LncRNA expression levels in PBMC from 5 patients with Relapsing Remitting (RR)-MS, 5 with Primary Progressive (PP)-MS and 5 age matched controls. Results were validated by Real time PCR in a further independent Italian cohort consisting of 30 PBMC samples from MS patients and 30 controls. Best hits were replicated, using droplet digital PCR, in a Belgian cohort made up by 24 MS patients and 23 controls.
In particular, in the Italian validation cohort ANRIL, TUG1, XIST (p< 0.0001) and SOX2OT (p< 0.001) were strongly down-regulated in RR-MS, while GOMAFU, HULC (p< 0.0001) and BACE-1AS (p< 0.001) showed a robust down-regulation both in RR and Progressive MS in comparison with controls.
NRON and TUG1 downregulation in MS patients compared with controls (p< 0.05 and p< 0.0001 respectively) was confirmed in the Belgian population.
Furthermore, considering the expression levels of LncRNAs known to be involved in brain function or neurological disorders, some important dysregulations emerged. The rationale of this study might then be used to set up a future study with the purpose of selecting potential biomarkers for disease aggressiveness and response to therapy.
LncRNAs profiling could thus represent a new challenge in the research of easy detectable biomarkers of disease susceptibility and progression.
Disclosure: nothing to disclose